Ignite Creation Date:
2024-05-06 @ 10:16 AM
Last Modification Date:
2024-10-26 @ 12:27 PM
Study NCT ID:
NCT03218007
Status:
COMPLETED
Last Update Posted:
2021-10-12
First Post:
2017-06-30
Brief Title:
A2 AR as a Novel Biomarkers for Physician Decision-making Improvement Evaluations Patients With Suspected Acute Coronary Syndrome But Negative Troponin
Sponsor:
Assistance Publique Hopitaux De Marseille
Organization:
Assistance Publique Hopitaux De Marseille
Study Overview
Official Title:
A 2A Receptor A2 AR as a Novel Biomarkers for Physician Decision-making Improvement Evaluations Patients With Suspected Acute Coronary Syndrome But Negative Troponin
Status:
COMPLETED
Status Verified Date:
2020-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
One proposed strategy is the stratification of troponin-negative patients with biomarker testing at presentation to facilitate the clinically-appropriate rapid discharge from the emergency department of patients who present with low-intermediate risk chest pain and conversely to triage appropriate Non sustained ST elevation acute coronary syndrome NSTE-ACS patients to Cardiology beds stress and non-invasive imaging modalities Biomarkers such as high-sensitivity troponin hs-cTn heart-type fatty acid-binding protein H-FABP CRP brain natriuretic peptide BNP and copeptin and ischemia-modified albumin are an important advance for diagnostic testing for ACS 4 Regarding novel biomarker testing at presentation the addition of these biomarkers demonstrated increased sensitivity at an acceptable QALY threshold but more evidence is needed 56 A reliable method for the diagnosis of minimal cardiac ischemia would meet a strong demand for the sensitive diagnosis of coronary artery disease in patients with chest pain but unremarkable ECGs and biomarkers Adenosine is an endogenous nucleoside cardioprotective agent Its cardiovascular effects are mediated throught the activation of A2A Receptor A2 AR and play a major role in the regulation of Coronary flow CF As altered coronary blood flow occurs in patients with CAD it has been showed that that A2AR expression and functional activity play a role in CAD In a previous studies the team have developped an agonist-like monoclonal antibody to study expression level of this receptor and their functional activity Recently Gariboldi demonstrated that measuring the expression level of A2AR on peripheral blood mononuclear cells PBMC represents a good tool to address in situ expression in coronary tissues of CAD patients
Detailed Description:
In the diagnostic setting of ACS expression and functionnaly activity of A2AR could be a sensitive detection method for ischemia It would be a powerful tool for risk stratification of patients presenting with chest pain but unremarkable ECG and blood tests the investigateors therefore designed a blind multicentrique prospective study to evaluate expression and functionnaly activity of A2AR in the management of undifferentiated chest pain The objective of the study was to evaluate diagnostic accuracy between this novel biomarkers A2AR and invasive and non -invasive evaluation of patients with suspected coronary artery disease CAD
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 2017-A01836-47 | OTHER | idrcb | None |